Bausch+Lomb has acquired an exclusive global license to a new technology for the treatment of ocular redness, one of the most common ophtalmological conditions, affecting millions of people worldwide. Licensed from Eye Therapies, a biopharmaceutical company, and developed in collaboration with Ora, a private research organization, the technology employs a ...
Buying a membership today will give you:
To continue reading this article register now.